Lupin Gains FDA Approval for Famotidine Injection USP Manufactured at Nagpur Facility

Lupin's Nagpur manufacturing facility has cleared a significant regulatory threshold, securing USFDA approval for Famotidine Injection USP, a generic equivalent of Pepcid injection intended for the U.S. market. For QA directors and plant heads overseeing sterile injectable operations, the approval signals that the Nagpur site has met the agency's current GMP expectations for parenteral manufacturing under 21 CFR Part 211.

Famotidine Injection USP is an H2-receptor antagonist indicated for conditions including gastroesophageal reflux and peptic ulcer disease, administered in hospital and clinical settings. Generic injectable approvals of this type require demonstrated sterility assurance, container-closure integrity, and process validation data aligned with ICH Q10 quality system principles, a compliance burden that makes each ANDA approval a meaningful operational benchmark for the originating site.

The Nagpur facility's approval adds to the broader pattern of Indian generic injectable manufacturers systematically expanding their U.S. market footprint through site-level GMP compliance. Each approval tied to a named facility carries direct implications for that site's inspection history and its standing in FDA's risk-based surveillance framework. Regulatory affairs leads tracking Lupin's U.S. portfolio will note this as further evidence of the company's intent to deepen its sterile injectables presence in a market where supply reliability and compliance continuity are under persistent regulatory scrutiny.

The U.S. generic injectable segment remains competitive, with pricing pressure offset by the complexity of maintaining sterile manufacturing standards that satisfy FDA expectations across successive inspection cycles. Lupin's ability to route this approval through Nagpur, rather than an established legacy site, reflects the operational investment required to qualify additional facilities for parenteral production at scale.

The Nagpur site's continued approval activity will serve as a measurable indicator of Lupin's capacity to sustain GMP compliance across its expanding sterile manufacturing network.

Source: Media4Growth via Indian Pharma Post, 14 May 2026.